MedTrace Logo

Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis

NCT00815906 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-08-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of single doses of SBI-087 in Japanese subjects with rheumatoid arthritis.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

SBI-087

IV, Single dose

DRUG

SBI-087

IV, Single dose

DRUG

SBI-087

SC, Single dose

DRUG

SBI-087

SC, Single dose

Sponsors & Collaborators

  • Emergent Product Development Seattle LLC

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-04-30
Completion
2012-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00815906 on ClinicalTrials.gov